In a memo regarding a pilot study of Hepatitis C screening, John Canavan noted that additional treatment costs "could be very substantial indeed" if interferon were to become the established therapy for Hepatitis C carriers.
Linked evidence
Chronology Information
Date:
Chapter/issue
Access to Treatment